SCHEMBL23555271

SCHEMBL23555271

CCN1CC2CC(C1)N2C(=O)C1CCOC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.35
PIK3CD O00329 4/20 0.34
PIK3R1 P27986 3/20 0.33
GRM5 P41594 1/20 0.33
RIPK1 Q13546 1/20 0.33
HSD11B1 P28845 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
NAMPT P43490 2/20 0.31
CACNA1G O43497 1/20 0.31
CACNA1H O95180 1/20 0.31
CACNA1I Q9P0X4 1/20 0.31
PRMT5 O14744 1/20 0.30
WDR77 Q9BQA1 1/20 0.30
KMT2A Q03164 1/20 0.30
CCR5 P51681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20160411 0.91 PIK3CD (0.41) RETPIK3CDHSD11B1SMN1; SMN2CACNA1G
SCHEMBL20070417 0.89 SMN1; SMN2 (0.35) RETPIK3CDPIK3R1GRM5RIPK1
SCHEMBL21158721 0.83 PIK3CD (0.36) RETPIK3CDGRM5RIPK1HTR1A
SCHEMBL20154481 0.81 PIK3CD (0.40) RETPIK3CDGRM5RIPK1
SCHEMBL23126226 0.79 RET (0.37) RETPIK3CDGRM5RIPK1NAMPT
SCHEMBL22031273 0.78 HSD11B1 (0.39) RETPIK3CDHSD11B1SMN1; SMN2KMT2A
SCHEMBL20160410 0.78 PIK3CD (0.39) RETPIK3CDGRM5RIPK1NAMPT
SCHEMBL22031235 0.77 HSD11B1 (0.38) RETHSD11B1SMN1; SMN2
SCHEMBL22812224 0.75 HSD11B1 (0.36) RETHSD11B1SMN1; SMN2KMT2A
SCHEMBL24767229 0.73 HSD11B1 (0.42) RIPK1HSD11B1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885PIK3CD 1191/4885PIK3R1 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.